Lb Pharmaceuticals INC (LBRX) — SEC Filings

Overview

Lb Pharmaceuticals INC (LBRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 23, 2026: LB Pharmaceuticals Inc. filed a Definitive Proxy Statement (DEFA14A) on April 23, 2026. The filing concerns additional definitive proxy soliciting materials. The company's mailing and business address is 575 Madison Avenue, New York, NY 10022.

Sentiment Summary

Across 10 filings, the sentiment breakdown is: 1 bullish, 6 neutral, 3 mixed. The dominant filing sentiment for Lb Pharmaceuticals INC is neutral.

Filing Type Overview

Lb Pharmaceuticals INC (LBRX) has filed 1 ARS, 1 DEFA14A, 1 EFFECT, 1 10-K, 3 8-K, 1 10-Q, 1 S-1/A, 1 S-1 with the SEC between Aug 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (10)

• ARS Filing — ARS · Apr 23, 2026
• LB Pharmaceuticals Files Definitive Proxy Statement — DEFA14A · Apr 23, 2026 Risk: low
  LB Pharmaceuticals Inc. filed a Definitive Proxy Statement (DEFA14A) on April 23, 2026. The filing concerns additional definitive proxy soliciting materials. Th
• EFFECT Filing — EFFECT · Apr 15, 2026
• LB Pharmaceuticals Advances Schizophrenia Drug to Phase 3, Targets $12B Market — 10-K · Mar 26, 2026 Risk: high
  LB Pharmaceuticals Inc. (LBRX) is a late-stage biopharmaceutical company focused on neuropsychiatric disorders, with its lead product candidate, LB-102, in Phas
• LB Pharmaceuticals Enters Material Definitive Agreement — 8-K · Nov 13, 2025 Risk: medium
  LB Pharmaceuticals Inc. announced on November 10, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its
• LB Pharmaceuticals Files 8-K — 8-K · Nov 12, 2025 Risk: low
  LB Pharmaceuticals Inc. filed an 8-K on November 12, 2025, reporting other events and financial statements. The filing does not contain specific details on new
• LB Pharma Slashes Losses, Boosts Cash by 10x in Q3 — 10-Q · Nov 6, 2025 Risk: medium
  LB Pharmaceuticals Inc. reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $13.733 million from $58.031 mi
• LB Pharmaceuticals Files 8-K with Bylaw Amendments — 8-K · Sep 12, 2025 Risk: low
  LB Pharmaceuticals Inc. filed an 8-K on September 12, 2025, reporting amendments to its articles of incorporation or bylaws and submitting financial statements
• LB Pharma's Schizophrenia Drug Nears Phase 3, Targets $12B Market — S-1/A · Sep 8, 2025 Risk: high
  LB Pharmaceuticals Inc. (LBRX) is a clinical-stage biopharmaceutical company focused on neuropsychiatric diseases, with its lead product candidate, LB-102, a Ph
• LB Pharmaceuticals Eyes Nasdaq Debut with Phase 3-Ready Schizophrenia Drug — S-1 · Aug 22, 2025 Risk: high
  LB Pharmaceuticals Inc. (LBRX) is a clinical-stage biopharmaceutical company focused on neuropsychiatric diseases, filing an S-1 for its initial public offering

Risk Profile

Risk Assessment: Of LBRX's 8 recent filings, 3 were flagged as high-risk, 2 as medium-risk, and 3 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Lb Pharmaceuticals INC's most recent 10-K filing (Mar 26, 2026):

• Revenue: $0
• Net Income: $-100.0M
• EPS: $0.00
• Debt-to-Equity: N/A
• Cash Position: $50.0M
• Operating Margin: N/A
• Total Assets: $150.0M
• Total Debt: $0

Key Executives

• Heather Turner
• Anna Eramo
• Scott Garland

Industry Context

The biopharmaceutical industry, particularly in the neuropsychiatric disorder space, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like LB Pharmaceuticals Inc. focus on addressing unmet medical needs with novel therapies. The market for antipsychotics is substantial, estimated at $12 billion in the U.S. in 2024, but competition is intense, with established players and ongoing innovation. Trends include the development of treatments targeting a broader range of symptoms (positive, negative, cognitive) and improved delivery methods like long-acting injectables to enhance patient adherence.

Top Tags

Biotechnology (4) · Pharmaceuticals (3) · Schizophrenia (3) · Clinical Stage (3) · corporate-governance (2) · Neuropsychiatry (2) · Bipolar Depression (2) · IPO (2) · proxy-statement (1) · Neuropsychiatric Disorders (1)

Key Numbers

• U.S. branded antipsychotic market: $12 billion — Represents the significant market opportunity for LB-102 as of 2024.
• Shares of Common Stock outstanding: 28,674,827 — As of March 23, 2026, indicating the current share count.
• Countries where amisulpride is approved: 50+ — Highlights the established clinical use of LB-102's derivative outside the U.S.
• Monthly amisulpride prescriptions: 2 million — In a subset of 16 European countries in 2023, demonstrating market demand for the drug class.
• Amisulpride prescriptions for schizophrenia: 60% — In Europe, indicating the primary target indication for LB-102.
• U.S. population affected by schizophrenia: 1% — Underscores the prevalence and potential patient population for LB-102.
• Decrease in average life expectancy for schizophrenia patients: 29 years — Emphasizes the severe impact of the disease and the need for effective treatments.
• Schizophrenia patients with cognitive impairment: 80% — Highlights an unmet need LB-102 aims to address.
• SEC File Number: 001-42831 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 81-1854347 — Company's tax identification number.
• Cash and Cash Equivalents: $269.7M — Increased from $22.9M at Dec 31, 2024, providing significant liquidity.
• Net Loss (9 months): $13.7M — Reduced by 76.3% from $58.0M in the prior year, indicating improved cost control.
• R&D Expenses (9 months): $8.26M — Decreased substantially from $50.79M in 2024, a key driver of loss reduction.
• Total Stockholders' Equity: $310.2M — Shifted from a $94.5M deficit to a positive position, strengthening the balance sheet.
• Common Stock Shares Outstanding: 25,299,102 — As of November 6, 2025, reflecting conversions and new issuances.

Related Companies

ROCHE · ALXN · VIFOR

Frequently Asked Questions